Officials say the $15.4 million multiyear agreement is for Oregon-based HemCon to continue development of its LHP, or freeze-dried human plasma, for eventual deployment in conflict zones. Under the deal, HemCon will work to secure U.S. Food and Drug Administration approval for the LHP product and delivery system.

Recent Army studies of HemCon's LHP have shown significant potential in the use of plasma as a resuscitation fluid in reducing battlefield mortality. Officials say the LHP initiative has been given a high priority status from the Army Medical Research and Materiel Command in an initiative to improve conflict zone survivability.

"This is a crucial initiative, and HemCon is honored to be the choice of the U.S. Army," John Morgan, HemCon president and chief executive officer, said in a statement. "Developing a lyophilized human plasma product and delivery system will be a significant evolution for battlefield and civilian trauma care."